Erratum to : Evaluation of Appropriate Use of SGLT2-inhibitors with Evaluation of Adopted Medicines and Application of Criterion
-
- Samura Masaru
- Department of Pharmacy, Yokohama General Hospital
-
- Ogawa Hisako
- Department of Pharmacy, Yokohama General Hospital
-
- Sennai Mitsuko
- Department of Pharmacy, Yokohama General Hospital
-
- Hori Shintaro
- Department of Pharmacy, Yokohama General Hospital
-
- Yamamoto Ayako
- Department of Pharmacy, Yokohama General Hospital
-
- Koshioka Sakura
- Department of Pharmacy, Yokohama General Hospital
-
- Hirose Naoki
- Department of Pharmacy, Yokohama General Hospital
-
- Sekine Hisakazu
- Department of Pharmacy, Yokohama General Hospital
Bibliographic Information
- Other Title
-
- 訂正
Abstract
<p>第43巻 第2号 93頁 引用文献 8)を次の通り訂正いたします</p><p>誤:8)Lee S, Monz BU, Clemens A, Brueckmann M, Lip GYH, Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a crosssectional analysis using the General Practice Research Database, BMJ Open, 2012, 2, e001768. doi:10.1136/bmjopen-2016-013774.</p><p>正:8)Lee S, Monz BU, Clemens A, Brueckmann M, Lip GYH, Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a crosssectional analysis using the General Practice Research Database, BMJ Open, 2012, 2, e001768. doi:10.1136/bmjopen-2012-001768.</p><p> 下線が訂正した部分</p>
Journal
-
- Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
-
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 43 (4), erratum_4-erratum_4, 2017
Japanese Society of Pharmaceutical Health Care and Sciences
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204776009728
-
- NII Article ID
- 130006685400
-
- ISSN
- 18821499
- 1346342X
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed